Christopher Ung
Chief Scientific Business Officer CellCarta
Seminars
Wednesday 7th October 2026
Panel Discussion: From Discovery to Deployment: How Frontier Tissue AI Augments Biomarker Development & Accelerates the Path to Bedside
11:20 am
- One Frontier Model, For Every Stage of Drug Development: Discover how a unified ecosystem powered by a single frontier AI model streamlines biomarker discovery, clinical trial stratification, regulatory-grade diagnostics, and global deployment to pathology labs. Platform agnostic development under one roof – no need for algorithm hand-offs or tedious integrations before deployment
- De-Risking CDx Timelines With Tissue AI: AI-driven biomarker signal detection reduces trial enrollment risk and enables more informed decisions from less tissue — shortening Rx-Dx co-development time
- Redefining Global Pathology Routine: Moving tissue biomarkers from isolated reference labs to global clinical routine powered by our extensive CRO partnerships and an active lab network
Thursday 8th October 2026
The CDx Model Needs to Change: What China Taught Us About Breaking Silos, Moving Faster, & Going Global
12:40 pm
Presentation Details to be Announced
